<DOC>
	<DOCNO>NCT00985244</DOCNO>
	<brief_summary>To assess whether maintenance treatment macrolide antibiotic COPD patient three exacerbation precede year inclusion decrease exacerbation rate year treatment .</brief_summary>
	<brief_title>Macrolide Maintenance Therapy Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>COPD characterize progressive development airflow limitation poorly reversible . Because poor understanding COPD pathogenesis , treatment mostly symptomatic new therapeutic strategy limit . There direct relationship severity disease intensity inflammatory response.One hypothesis persistent airway inflammation presence recurrent infection responsible condition . Macrolide antibiotic bacteriostatic well anti-inflammatory property . This clinical trial investigate whether maintenance treatment macrolide antibiotic 1 year people 3 exacerbation precede year inclusion decrease exacerbation rate year treatment .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Diagnosis COPD accord GOLD criterion ( FEV1/FVC &lt; 70 % ) , classification GOLD I ( FEV1 70100 % predict ) , GOLD II ( FEV1 5070 % predict ) , GOLD III ( FEV1 30 50 % predict ) GOLD IV ( FEV1 ≤ 30 % predict ) Age ≥ 18 year Three exacerbation COPD one year course prednisone and/or antibiotic therapy start Clinically stable 1 month . Patients free COPD exacerbation respiratory tract infection within month prior involvement study receive high dose systemic glucocorticoid antibiotic period Informed consent Use antibiotic high dose systemic steroid within month prior involvement study . Addition inhalation steroid patient 's therapy regimen , shortly enter study . Pregnant lactate woman . Allergy macrolides . Liver disease ( alanine transaminase and/or aspartate transaminase level 2 time upper limit normal ) . Asthma , define episodic symptom airflow obstruction reversible bronchodilator , assess lung function test . Presence malignancy clinically active . Bronchiectasis . Malignancy kind subject treatment monitor part follow treatment . Heart failure . Use drug adversely interact macrolides therapeutic monitoring undertaken .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>COPD exacerbation</keyword>
	<keyword>macrolide</keyword>
	<keyword>diseae progression</keyword>
	<keyword>bacterial colonisation</keyword>
</DOC>